GlaxoSmithKline (GSK) announced a $30 billion investment in US research, development, and manufacturing over the next five years. This includes $1.2 billion for advanced manufacturing, AI, and digital technologies, creating next-generation facilities. The announcement coincides with President Trump's UK state visit and follows similar large investments from other pharmaceutical companies, possibly influenced by the Trump administration's push for increased US manufacturing and lower drug prices. GSK's investment will involve a new Pennsylvania biologics factory and upgrades to existing sites.

Prepared by Christopher Adams and reviewed by editorial team.